IgG Antibodies to GlcNAcβ and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment

Table 6

Association of the level of anti-GlcNAcβ Abs with portal inflammation score.

Abs	Genotype	Stage ()	Score ()	Median ()
GlcNAcβ	1b	0–4	0–2	0.144	0.004 (S0–2 vs. S3–4)
			3–4	0.513
	3a	0–4	0–2	0.212	0.002 (S0–2 vs. S3–4)
			3–4	0.487
	1b and 3a	0–2	0–2	0.166	<0.001 (S0–2 vs. S3)
			3	0.531
		0–4	0–2	0.166	<0.001 (S0–2 vs. S3–4)
			3–4	0.474